Sun Pharmaceutical Industries Limited (SUNPHARMA) establishes endowed professorship at Mount Sinai to advance dermatologic care.
Sun Pharmaceutical Industries Limited (SUNPHARMA) shares two-year efficacy and safety data for LEQSELVI® in severe alopecia areata at EADV Congress 2026.
Sun Pharma secures global licensing for Lerodalcibep, a PCSK9 inhibitor, to expand its Innovative Medicines portfolio and address cardiovascular care needs.
Sun Pharmaceutical Industries Limited commits to U.S. medicines pricing and access agreements, extending MFN pricing to state Medicaid programs.
Sun Pharma reports Organon shareholder approval for acquisition, marking a significant step towards completing the merger transaction.
Sun Pharmaceutical Industries Limited (SUNPHARMA) announced approval to manufacture and market generic semaglutide in South Africa.
Sun Pharma to present long-term follow-up data on UNLOXCYT™ at ASCO 2026, showing nearly 27% complete response rate.